WHO/Q. Mattingly
© Credits

Antimicrobial resistance

    Overview

    Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.

    AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others.

    Antimicrobials - including antibiotics, antivirals, antifungals and antiparasitics - are medicines used to prevent and treat infections in humans, animals and plants. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”.

    WHO’s AMR response

    4 key priorities

    lead global efforts, drive public health impact, promote R&D, monitor AMR burden and response

    WHO AMR priorities

    Addressing SDGs

    Mitigating AMR will have a huge impact on reaching 6 of the 17 sustainable development goals (SDGs)

    AMR & SDGs

    1.2 trillion USD

    additional health expenditure per year expected by 2050 due to the rise of antimicrobial resistance.

    "Together with our partners, we’re also stepping up the fight against antimicrobial resistance, one of the most urgent health threats of our time."

    Dr. Tedros Adhanom Ghebreyesus, WHO Director-General

    Publications

    All →
    Bacterial vaccines in clinical and preclinical development 2021

    The World Health Organization’s (WHO) “An analysis of bacterial vaccines in preclinical and clinical development: 2021” is the first...

    Stocktaking to advance implementation of For the Future: Towards the Healthiest and Safest Region

    This information document summarizes the stocktaking exercises conducted to articulate the progress of For the Future, our vision in the Western Pacific...

    Antimicrobial Resistance Multi-Partner Trust Fund annual report 2021

    This publication presents the Antimicrobial Resistance Multi-Partner Trust Fund (AMR MPTF) Annual Report 2021 and highlights progress made by the...

    2021 Antibacterial agents in clinical and preclinical development: an overview and analysis

    The World Health Organization’s (WHO) “2021 Antibacterial agents in clinical and preclinical development: an overview and analysis” report...